Advances in biologic agents for the treatment of rheumatoid arthritis

Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry

Volumn 9, Issue 1, 2010, Pages 24-34

  Gur, Ali ^a   Oktayoglu, Pelin ^b  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b Batman Region State Hospital   (Turkey)

Author keywords

Biologic agents; Disease modifying anti rheumaticdrugs; Monoclonal antibody; Rheumatoid arthritis; TNF alpha blocker

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIRHEUMATIC AGENT; ATACICEPT; BAMINERCEPT; BUCILLAMINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; DENOSUMAB; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY LM 609; NONSTEROID ANTIINFLAMMATORY AGENT; OCRELIZUMAB; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TACROLIMUS; TOCILIZUMAB; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; BIOTECHNOLOGY; BLOOD PRESSURE; CELLULITIS; CLINICAL PRACTICE; CLINICAL TRIAL; DIVERTICULITIS; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPNEA; FOLLOW UP; GASTROENTERITIS; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INFECTIOUS ARTHRITIS; INFUSION REACTION; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; LOW DRUG DOSE; LYMPHOCYTE ACTIVATION; OSTEOMYELITIS; OSTEOPOROSIS; PATHOGENESIS; PERIANAL ABSCESS; PNEUMONIA; PSORIATIC ARTHRITIS; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; WHEEZING;

EID: 77950821279     PISSN: 18715230     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152310790711656     Document Type: Review

References (134)

1. Lee, D.M.; Weinblatt, M.E. Rheumatoid arthritis. Lancet, 2001, 358, 903-911.
2. Gabriel, S.E.; Crowson, C.S., Kremers, H.M.; Doran, M.F.; Turesson, C.; O'Fallon, W.M.; Matteson, E.L. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum., 2003, 4, 54-58.
3. Mikuls, T.R.; Saag, K.G.; Criswell, L.A.; Merlino, L.A.; Kaslow, R.A.; Shelton, B.J.; Cerhan, J.R. Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women's Health Study. Ann. Rheum. Dis., 2002, 61, 994-999.
4. Pincus, T.; Kavanaugh, A.; Sokka, T. Benefit/risk of therapies for rheumatoid arthritis: underestimation of the 'side effects' or risks of RA leads to underestimation of the benefit/risk of therapies. Clin. Exp. Rheumatol., 2004, 22(Suppl. 35), 2-11.
5. Ladislav, š.; Jiøoí, V.; Karel, P.; Caroline, O.; Steffen, G. Prospective new biological therapies for rheumatoid arthritis. Autoimmun. Rev., 2009, 9(2), 102-107.
6. Scrivo, R.; Di Franco, M.; Spadaro, A.; Valesini, G. The immunology of rheumatoid arthritis. Ann. NY Acad. Sci., 2007, 1108, 312-322.
7. Teitelbaum, S.L. Osteoclasts; culprits in inflammatory osteolysis. Res. Ther., 2006, 8(1), 201.
8. Tran, C.N.; Lundy, S.K.; Fox, D.A. Synovial biology and T cells in rheumatoid arthritis. Pathophysiology, 2005, 12(3), 183-189.
9. Sweiss, N.J.; Hushaw, L.L. Biologic agents for rheumatoid arthritis. J. Infusion Nurs., 2009, 32(1), 4-17.
10. Hennigan, S.; Kavanaugh, A. Therapy with immunoglobulin: applications for monoclonal antibodies. Ther. Clin. Risk Manag., 2008, 4(4), 767-775.
11. Stowell, C.P. Therapy with immunoglobulin: applications for monoclonal antibodies. J. Infus. Nurs., 2006, 29(3)(Suppl), S29-S44.
12. Choy, E.H.S.; Panayi, G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med., 2001, 344(12), 907-916.
13. Malvern, PA. Centocor, Inc; 2002 Arthritis Rheum., 2000, 43(suppl), S269.
14. Knight, D.M.; Trinh, H.; Le, J.; Siegel, S.; Shealy, D.; McDonough, M.; Scallon, B.; Moore, M.A., Vilcek, J.; Daddona, P. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol., 1993, 30, 1443-1453.
15. Scallon, B,J.; Moore, M.A.; Trinh, H.; Nedelman, M.; Brennan, F.M.; Feldmann, M.; Ghrayeb, J. Functional comparisons of different tumour necrosis factor receptor/IgG fusion proteins. Cytokine, 1995, 7, 251-259.
16. Kohler, S.; Thiel, A.; Radbruch, A.; Sieper, J.; Braun, J. High sensitivity cytometric analysis of membrane and receptor bound TNF-α on T cells effects of anti-TNF treatment in vitro. Arthritis Rheum., 2000, 43, S101.
17. Weaver, L.A. Differentiating the New Rheumatoid Arthritis Biologic Therapies. J. Clin. Rheumatol., 2003, 9(2), 99-114.
18. Straub, RH.; Härle, P.; Sarzi-Puttini, P.; Cutolo, M. Tumor necrosis factor-neutralizing therapies improve altered hormone axes. An alternative mode of anti-inflammatory action. Arthritis Rheum.,2006, 54, 2039-2046 .
19. Lipsky, PE.; van der Heijde, DM.; St Clair, EW.; Furst, DE.;Breedveld, FC.; Kalden, JR.; Smolen, J.S.; Weisman, M.; Emery,P.; Feldmann, M.; Harriman, GR; Maini, RN. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N. Engl. J. Med., 2000, 343, 1594-15602.
20. Kohno, T.; Louie, J. S.; Stevens, S. R. Differences in Fc receptorand C1q binding in tumor necrosis factor (TNF) antagonists may contribute to differences in mechanisms of action. J. Invest. Dermatol., 2005, 124(4), A111.
21. Lobo, E.D., Hansen, R.J., Balthasar, J.P. Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci., 2004, 93, 2645-2668.
22. Tracey, D.; Klareskog, L.; Sasso, E.H; Salfeld, J.G.; Tak, P.P.Tumor necrosis Factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther., 2008, 111, 244-279.
23. Bathon, J.M.; Martin, R.W.; Fleischmann, R.M.; Tesser, J.R.;Schiff, M.H.; Keystone, E.C.; Genovese, M.C.; Wasko, M.C.; Moreland, L.W.; Weaver, A.L.; Markenson, J.; Finck, B.K. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med., 2000, 343, 1586-1593.
24. Genovese, MC.;Bathon, JM.; Martin, RW; Fleischmann, R.M.; Tesser, J.R.; Schiff, M.H.; Keystone, E.C.; Wasko, M.C.; Moreland, L.W.; Weaver, A.L.; Markenson, J.; Cannon, G.W.; Spencer-Green, G.; Finck, B.K. Etanercept versus methotrexate in patients with early rheumatoid arthritis. Arthritis Rheum 2002;46:1443-1450
25. Genovese, M; Martin, R; Fleischmann, R. Etanercept (Enbrel) in early erosive rheumatoid arthritis (ERA Trial): observations at 3 years. Arthritis Rheum., 2001, 44, S78.
26. Seattle, W.A. Enbrel® [package insert]. Immunex Corporation, 2002.
27. Frank, M.M.; Fries, L.F. In: Complement Paul WE, Ed. Fundamental Immunology. New York: Raven Press, 1989, pp. 679-701.
28. Berke, G. In: Functions and mechanisms of lysis induced by cytotoxic T lymphocytes and natural killer cells. Paul W, Ed. Fundamental Immunology. New York: Raven Press, 1989, pp. 735-764.
29. Kempeni, J. Preliminary results of early clinical trials with the fully human anti-TNF α monoclonal antibody D2E7. Ann. Rheum. Dis., 1999, 58(Suppl 1), I70-I72.
30. Furst, DE.; Schiff, MH.; Fleischmann, RM.; Strand, V.; Bibara, CA.; Compagnone, D. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J. Rheumatol., 2003, 30(12), 2563-2571.
31. Van de, Putte.; LBA, Rau R.; Breedveld, F.C.; Kalden, J.R.; Malaise, M.G.; Schattenkirchner, M.; Emery, P.; Burmester, G.R.; Zeidler, H.; Dressler, R.; Compagnone, D.; Kempeni, J.; Kupper, H. One year efficacy results of the fully human anti-TNF antibody D2E7 in rheumatoid arthritis. Arthritis Rheum., 2000, 43(suppl), S269.
32. Keystone, E.; Weinblatt, M.E.; Furst, D.E.; Weisman, M.; Moreland, L.; Birbara, C.; Fischkoff, S.; Chartash, E. The ARMADA trial: A double-blind placebo controlled trial of the fully human anti-TNF monoclonal antibody, adalimumab (D2E7), in patients with active RA on methotrexate (MTX). Arthritis Rheum., 2000, 44(9), S213 .
33. Chang, J.; Lichtenstein, G.R. Drug insight: antagonists of tumornecrosis factor- αin the treatment of inflammatory bowel disease. Gastroenterol. Hepatol., 2000, 3, 220-228 .
34. Food and Drug Administration. FDA labelling information. FDA web site [online], 2008. 〈 http://www.fda.gov/cder/foi/label/2008/125160s000lbl
35. Nesbitt, A.; Fossati, G.; Bergin, M.; Stephens, P.; Stephens, S.;Foulkes, R.; Brown, D.; Robinson, M.; Bourne, T. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other antitumor necrosis factor αagents. Inflamm. Bowel Dis., 2007, 13, 1323-1332.
36. Keystone, E.; van der Heijde, D.; Mason, D.J. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty two week, phase III, multicenter, randomized, double-blind, placebo controlled, parallel group study. Arthritis Rheum., 2008, 58, 3319-3329.
37. Smolen, J.; Landewe, R.B.; Mease, P.J.; Brzezicki, J.; Mason, D.;Luijtens, K.; van Vollenhoven, R.F.; Kavanaugh, A.; Schiff, M.; Burmester, G.R.; Strand, V.; Vencovsky, J.; van der Heijde, D. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis. The RAPID 2 study. Ann. Rheum. Dis., 2009, 68(6), 797-804.
38. Van der Heijde, D.; Weinblatt, M.; Landerwe, R.B.; Goel, N.;Wells, A.F.; Fleischmann, R.M. Inhibition of progression of structural damage by week 16 with certolizumab pegol: results from the RAPID trials. Arthritis Rheum., 2008, 57, (Suppl), S529.
39. Keystone, E. Recent concepts in the inhibition of radiographic progression with biologics. Curr. Opin. Rheumatol., 2009, 21, 231-237.
40. Kay, J.; Matteson, EL.; Dasgupta, B.; Nash, P.; Durez, P.; Hall, S.; Hsia, EC.; Han, J.; Wagner, C.; Xu, Z.; Visvanathan, S.; Rahman, MU. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo- controlled, dose-ranging study. Arthritis Rheum., 2008, 58(4), 964-975.
41. Kavanaugh, A.; McInnes, I.; Mease, P.; Krueger, G.G.; Gladman, D.; Gomez-Reino, J.; Papp, K.; Zrubek, J.; Mudivarthy, S.; Mack, M.; Visvanathan, S.; Beutler, A. Golimumab, a new, human, TNF-alpha antibody administered as a monthly subcutaneous injection inpsoriatic arthritis: 24-week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL Study. Arthritis Rheum., 2007, 56(12), 4308-4309.
42. Inman, R.D.; Davis, J.C. Jr., Heijde, D.; Diekman, L.; Sieper, J.; Kim, S.I.; Mack, M.; Han, J.; Visvanathan, S.; Xu, Z.; Hsu, B.; Beutler, A.; Braun, J. Efficacy and safety of golimumab in patientswith ankylosing spondylitis: results of a randomized, double-blind,placebo-controlled, phase III trial. Arthritis Rheum., 2008, 58(11), 3402-3412.
43. Ken, JB. Biologic therapies in Rheumatoid arthritis. Curr. Rheum.Rep., 1999, 1, 157-163.
44. Sharma, R.; Verma, U. A novel therapeutic approach in rheumatoid arthritis. Ind. J. Pharmacol., 2005, 36, 265-266.
45. Vila, A.T.; Puig, L.; Fernandez-Figueras, M.T.; Laiz, A.M.; Vidal,D.; Alomar, A. Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: Clinicopathological study of patients. Br. J. Dermatol., 2005, 153, 417-423.
46. Cohen, S.; Hurd, E.; Cush, J. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-fourweek, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum., 2002, 46, 614-624.
47. Cohen, S.B.; Moreland, L.W.; Cush, J.J.; Greenwald, M.W.; Block, S.; Shergy, W.J.; Hanrahan, P.S.; Kraishi, M.M.; Patel, A.; Sun, G.; Bear, M.B. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate Ann. Rheum. Dis., 2004, 63, 1062-1068.
48. Firestein, G.S.; Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J. Clin. Rheumatol., 2005, 11(Suppl), S39-S44.
49. Rose, H.M.; Ragan, C.; Pearce, E. Differential agglutination of normal and sensitized sheep erythrocytes by sera ofpatients with rheumatoid arthritis. Proc. Soc. Exo. Biol. Med., 1948, 68, 1-6.
50. Holman, H.R.; Kunkel, H.G. Afinity between the lupus erythematosus serum factor and cell nuclei and nucleoprotein. Science, 1957, 126, 162-163.
51. Dorner, T.; Burmester, G.R. The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr. Opin. Rheumatol., 2003, 15, 246-252.
52. Gao, IK.; Haas-Wohrle, A.; Mueller, KG.; Lorenz, HM.; Fiehn, C. Determination of anti- CCP antibodies in patients with suspected rheumatoid arthritis: does it help to predict the diagnosis before referral to a rheumatologist? Ann. Rheum. Dis., 2005, 64, 1516-1517.
53. Mimori, T. Clinical signi. cance of anti-CCP antibodies in rheumatoid arthritis. Intern. Med., 2005, 44, 1122-1126.
54. van Gaalen, F.A.; Visser, H.; Huizinga, T.W. A comparison of the diagnostic accuracy and prognostic value of the first and second anticyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritis. Ann. Rheum. Dis. 2005, 64, 1510-1512.
55. Vossenaar, ER.; van Venrooij, WJ. Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis. Arthritis Res. Ther., 2004, 6, 107-111.
56. Kastbom, A.; Strandberg, G.; Lindroos, A.; Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann. Rheum. Dis., 2004, 63, 1085-1089.
57. Alessandri, C.; Bombardieri, M.; Papa, N.; Cinquini, M.; Magrini, L.; Tincani, A.; Valesini, G. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti TNF-alpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann. Rheum. Dis., 2004, 63, 1218-1221.
58. Teng, YKO.; Huizinga, TWJ.; van Laar, JM. Targeted therapies in rheumatoid arthritis:Focus on rituximab. Biologics, 2007, 1(4) 325-333.
59. Tedder, T.F.; Engel, P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol. Today, 1994, 15, 450-454.
60. Eisenberg, R.; Looney, R.J. The therapeutic potential of anti-CD20 'what do B-cells do? Clin. Immunol., 2005, 117, 207-213.
61. Levesque, MC.; St Clair, EW. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. J. Allergy Clin. Immunol., 2008, 121, 13-21.
62. Hultin, L.E.; Hausner, M.A.; Hultin, P.M.; Giorgi, J.V. CD20 (pan- B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry, 1993, 14, 196-204.
63. Quintanilla-Martinez, L.; Preffer, F.; Rubin, D.; Ferry, J.A.; Harris, N.L.; CD20+ T-cell lymphoma. Neoplastic transformation of a normal T-cell subset. Am. J. Clin. Pathol., 1994, 102, 483-489.
64. Martin, F.; Chan, A.C. B cell immunobiology in disease: evolving concepts from the clinic.Annu. Rev. Immunol., 2006, 24, 467-496.
65. Di Gaetano, N.; Cittera, E.; Nota, R. Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol., 2003, 171, 1581-1587.
66. Levesque, M.C. Translational Mini-Review Series on B cell-Directed Therapies: Recent advances in b cell-directed biological therapies for autoimmune disorders. Clin. Exp. Immunol., 2009, 157, 198-208.
67. Reff, M.E; Carner, K.; Chambers, K.S.; Chinn, P.C.; Leonard, J.E.;Raab, R.; Newman, RA.; Hanna, N.; Anderson, D.R. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood, 1994, 83, 435.
68. Maloney, DG.; Smith, B.; Appelbaum, FR. The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct antiproliferative activity and induction of apoptosis in C D20 positive non-Hodgkin's lymphoma (NHL) cell lines. Blood, 1996, 88(Suppl 1), 637. .
69. Genberg, H.; Hansson, A., Wernerson, A.; Tyden, G. Effective Bcell depletion in peripheral blood and tissue by single-dose rituximab in kidney transplant recipients: A pilot study. Am. J. Transplant., 2005, 5(Suppl 11), 397.
70. Schroder, C.; Azimzadeh, A.M.; Wu, G.; Price, J.O. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl. Immunol., 2003, 12, 19-28.
71. Pescovitz, MD. Rituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of Action. Am. J. Transplant., 2006, 6, 859-866.
72. Cohen, S.B.; Emery, P.; Greenward, M.W.; Dougados, M.; Furie, R.A.; Genovese, M.C.; Keystone, E.C.; Loveless, J.E.; Burmester, G.R.; Cravets, M.W.; Hessey, E.W.; Shaw, T.; Totoritis, M.C.; REFLEX Trial Group. For the REFLEX trial group. Rituximab for rheumatoid arthritis refractory to antitumor necrosis factor therapy:results of a multicenter randomized, double-blind, placebocontrolled phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum., 2006, 54, 2793-2806.
73. Keystone, E.; Emery, P.K.; Peterfy, C.D.; Tak, P.P.; Cohen, S.B.; Genoveses, M.C.; Williams, S.; Hagerty, D.; Cravetss, M.W.; Shaw, T. Inhibition of radiographic progression with rituximab is not dependent on clinical efficacy: results from a study in rheumatoidarthritis patients with inadequate response to one or more TNF inhibitors (REFLEX). Ann. Rheum. Dis., 2007, 66(Suppl 11), 431.
74. Arnett, F.C.; Edworthy, S.M.; Bloch, D.A.; McShane, D.J.; Fries,JF.; Cooper, NS.; Healey, L.A.; Kaplan, S.R.; Liang, M.H.; Luthra,H.S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum.,1988, 31, 315-324.
75. Renato, G.M. B Cell Depletion in Early Rheumatoid Arthritis: A New Concept in Therapeutics. Ann. N.Y. Acad. Sci., 2009, 1173, 729-735.
76. Emery, P.; Rigby, W.F.; Combe, B. Efficacy and safety of rituximab as first-line biologic therapy in patients with active rheumatoid arthritis; Results of a phase III randomized controlled study.(SERENE). Arthritis Rheum., 2008, 58(Suppl 9), 302-364.
77. Deodhar, A.; Isaacs, J.; Rigby, W. Improved quality of life with rituximab as first-line biological therapy of patients with active rheumatoid arthritis:Results of a phase III randomized controlled study. (SERENE). Arthritis Rheum., 2008, 58(Suppl 9), s302-365.
78. Rituximab (Rituxan) for rheumatoid arthritis. Med. Lett. Drugs Ther., 2006, 48, 34-35 .
79. Callen, JP. Complications and adverse reactions in the use of newer biologic agents. Semin. Cutan. Med. Surg., 2007, 26, 6-14.
80. Edwards, J.C.; Szczepanski, L.; Szechinski, J. Efficacy of B-celltargeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med., 2004, 350, 2572-2581. (Pubitemid 38758544)
81. Emery, P.; Fleischmann, R.; Filipowicz-Sosnowska, A. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum., 2006, 54, 1390-1400.
82. Genovese, MC.; Kaine, JL.; Lowenstein, MB.; Giudice, JD.; Baldassare, A.; Schechtman, J.; Fudman, E.; Kohen, M.; Gujrathi, S.; Trapp, RG.; Sweiss, NJ.; Spaniolo, G.; Dummer, W.; ACTION Study Group. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum., 2008, 58, 2652-2661.
83. van der Kolk, L.E.; Grillo-Lopez, A.J.; Baars, J.W.; Hack, C.E.; van Oers, M.H.; Complement activation plays a key role in the side-effects of rituximab treatment. Br. J. Haematol., 2001, 115, 807-811.
84. Greene, J.L.; Leytze, G.M.; Emswiler, J.; Peach, R.; Bajorath, J.; Cosand, W.; Linsley, P.S. Covalent dimerization of CD28/ CTLA- 4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. J. Biol. Chem., 1996, 271, 26762-26771.
85. Peach, R.J.; Bajorath, J.; Brady, W.; Leytze, G.; Greene, J.; Naemura, J.; Linsley, PS. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1. J. Exp. Med., 1994, 180, 2049-2058.
86. Linsley, P.S.; Greene, J.L.; Brady, W.; Bajorath, J.; Ledbetter, J.A.;Peach, R. Human B7-1 (CDS0) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity, 1994, 1,793-801.
87. Nogid, A.; Pham, D.Q. Role of Abatacept in the Management of Rheumatoid Arthritis. Clin. Ther., 2006, 11(28), 1764-1778.
88. Falgarone, G.; Semerano, L.; Sandrine, R.; Boissier, M.C. Targeting lymphocyte activation to treat rheumatoid arthritis. Joint Bone Spine, 2009, 76, 327-332.
89. Genovese, M.C.; Becker, J.C.; Schiff, M.; Luggen, M.; Sherrer, Y.; Kremer, J.; Birbara, C.; Box, J.; Natarajan, K.; Nuamah, I.; Li, T.; Aranda, R.; Hagerty, D.T.; Dougados, M. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N.Engl. J. Med., 2005, 353, 1114-1123.
90. Genovese, M.C.; Schiff, M.; Luggen, M.; Becker, J.C.; Aranda, R.; McCann, T.; Schmidely, N.; Le Bars, M.; Dougados, M. Sustained efficacy and safety through 2 years in patients with rheumatoid arthritis (RA) in the long-term extension of the ATTAIN trial. Arthritis Rheum., 2006, 54(Suppl), S244.
91. Roth, A.R.; Finckh, A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res. Ther., 2009, 11(1).
92. Kremer, J.M.; Westhovens, R.; Leon, M.; Di Giorgio, E.; Alten, R.; Steinfeld, S.; Russell, A.; Dougados, M.; Emery, P.; Nuamah, I.F.; Williams, G.R.; Becker, J.C.; Hagerty, D.T.; Moreland, L.W. Treatment of rheumatoid arthritis by selective inhibition ofT-cell acti-vation with fusion protein CTLA41g. N. Engl. J. Med., 2003, 349, 1907-1915.
93. Kremer, J.M.; Dougados, M.; Emery, P.; Durez, P.; Sibilia, J.; Shergy, W.; Steinfeld, S.; Tindall, E.; Becker, J.C.; Li, T.; Nuamah, I.F.; Aranda, R.; Moreland, L.W. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelvemonth results of a phase IIb, double-blind, randomized, placebocontrolled trial. Arthritis Rheum., 2005, 52, 2263-2271.
94. Kremer, J.M.; Genant, H.K.; Moreland, L.W.; Russell, A.S.; Emery, P.; Abud-Mendoza, C.; Szechinski, J.; Li, T.; Ge, Z.; Becker, J.C.; Westhovens, R. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial. Ann. Intern. Med., 2006, 144, 865-876.
95. Combe, B.; Weinblatt, M.; Birbara, C.; Ruderman, E.; Greenwald, M.; White, A.; Li, T.; Becker, JC.; Aranda, R.; Keystone, E. Safety and patient-reported outcomes associated with abatacept in the treatment of rheumatoid arthritis patients who received background disease modifying anti-rheumatic drugs (DMARDS): The ASSURE trial. RA treatment: Biologics and gene therapy. Arthritis Rheum., 2005, 52(9), 709-710.
96. Study IM101031. Available at: www.fda.gov/OHRMS/DOCKETS/ac/05/slides/ 2005-4170S104FDA-Hull.ppt. [Accessed August 3, 2006].
97. Orencia (abatacept) injection [package insert]. Princeton, NJ: Bristol- Myers Squibb Company; 2005.
98. US Food and Drug Administration. Abatacept label information.http://www. fda.gov/cder/foi/label/2007/125118s0016lbl.pdf. (Accessed April 15, 2007).
99. Weinblatt, M.; Schi, M.; Goldman, A.; Kremer, J.; Luggen, M.; Li, T.; Chen, D.; Becker, JC. Ann. Rheum. Dis., 2007, 66, 228-234.
100. Weinblatt, M.; Combe, B.; Covucci, A.; Aranda, R.; Becker, JC.; Keystone, E.; Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Arthritis Rheum., 2006, 54, 2807-2816.
101. Smolen, J.S.; Koeller, M.; Weisman, M.H.; Emery, P. New therapies for treatment of rheumatoid arthritis. Lancet, 2007, 370, 1861-1874.
102. Nakahara, H.; Song, J.; Sugimoto, M.; Hagihara, K.; Kishimoto, T.; Yoshizaki, K.; Nishimoto, N. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum., 2003, 48, 1521-1529.
103. Tamura, T.; Udagawa, N.; Takahashi, N.; Miyaura, C.; Tanaka, S.; Yamada, Y.; Koishihara, Y.; Ohsugi, Y.; Kumaki, K.; Taga, T. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc. Natl. Acad. Sci. USA, 1993, 90, 11924-11928.
104. Pawlik, A.; Wrzesniewska, J.; Florczak, M.; Gawronska-Szklarz, B.; Herczynska, M. IL-6 promoter polymorphism in patients with rheumatoid arthritis. Scand. J. Rheumatol., 2005, 34, 109-113. (Pubitemid 40694829)
105. Nishimoto, N.; Nishimoto N. Interleukin 6 in rheumatoid arthritis. Curr. Opin. Rheumatol., 2006, 18, 277-281.
106. Choy, E.H.S.; Isenberg, DA.; Garrood, T.; Farrow, S.; Ioannou, Y.;Bird, H.; Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis. Arthritis Rheum., 2002, 46, 3143-3150.
107. Nishimoto, N.; Yoshizaki, K.; Miyasaka, N.; Yamamoto, K.; Kawai, S.; Takeuchi, T. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody. A multicenter, doubleblind, placebo-controlled trial. Arthritis Rheum., 2004, 50, 1761-1769.
108. Nishimoto, N.; Miyasaka, N.; Yamamoto, K.; Kawai, S.; Takeuchi,T.; Azuma, J. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response tomethotrexate (SATORI): significant reduction in disease activityand serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod. Rheumatol., 2009, 19, 12-19.
109. Nishimoto, N.; Hashimoto, J.; Miyasaka, N.; Yamamoto, K.;Kawai, S.; Takeuchi, T.; Nurata, N.; vander Heijde, D.; Kishimoto,T. Study of active controlled monotherapy used for rheumatoid arthritis,an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomized controlled trial of tocilizumab. Ann. Rheum. Dis., 2007, 66, 1162-1167.
110. Emery, P.; Keystone, E.; Tony, HP.; Cantagrel, A.; van, Vollenhoven, R.; Sanchez, A. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomized placebo-controlled trial. Ann. Rheum. Dis., 2008, 67, 1516-1523.
111. Arnett, F.C.; Edworthy, S.M.; Bloch, D.A.; McShane, D.J.; Fries, J.F.; Cooper, N.S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum., 1988, 31, 315-324.
112. Study Group of the Ministry of Health, Labour and Welfare. Diagnostic and therapeutic manual of rheumatoid arthritis. Diagnostic manual and evidence-based treatment guidelines (in Japanese).Tokyo: Japan Rheumatism Foundation; 2004.
113. Koiki, R.; Harigai, M.; Atsumi, T.; Amano, K.; Kawai, S.; Saito, K.; Saito, T.; Yamamura, M.; Matsubara, T.; Miyasaka, N. Japon College of Rheumatology 2009 guidelines for the use of tociluzumab, a humanized anti-interleukin 6 receptor monoclonal antibody, in rheumatoid arthritis. Mod. Rheumatol., 2009, 19, 351-357.
114. Maini, R.N.; Taylor, P.C.; Szechinski, J. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum., 2006, 54, 2817-2829.
115. Nishimoto, N.; Hashimoto, J.; Miyasaka, N. Study of active controlled monotherapy used for rheumatoid arthritis, and IL-6 inhibitor (SAMURAI): -Evidence of clinical and radiographic bene. T from an x-ray reader-blinded randomized controlled trial of tocilizumab. Ann. Rheum. Dis., 2007, 66, 1162-1167.
116. Chau, L.S.; Mok, C.C.; Choy, E. Non tumor necrosis factor biological therapies for rheumatoid arthritis. Am. J. Rheumatol., 2005,8, 77-83.
117. Wendling, D., Racadot, E.; Wijdenes, J. Treatment of severe rheumatoid arthritis by anti- interleukin-6 monoclonal antibody. J. Rheumatol., 1993, 20, 259-262.
118. Nishimoto, N.; Yoshizaki, K.; Maeda, K.; Deguchi, H.; Sato, B.Toxicity, Pharmacokinetics and dose-depending study of repetitive treatment with humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis phase I/II clinical study. J. Rheumatol., 2003, 30, 1426-1435.
119. Singh, R.; Robinson, D.B., Gabalawy, H.S.; Emerging biologic therapies in rheumatoid arthritis: Cell targets and cytokines. Curr.Opin. Rheumatol., 2005, 2,38-43.
120. Yokota, S.; Miyamae, T.; Imagawa, T.; Katakura, S., Kurosawa, R.; Mori, M.; Clinical study of tocilizumab in children with systemic- onset juvenile idiopathic arthritis. Clin. Rev. Allergy Immunol.,2005, 28, 231-238.
121. Sharma, R.; Sharma, CL.; Mahajan, A. Biological agents targeting beyond TNF alpha. Indian J. Crit. Care Med., 2008, 4, 181-189.
122. Baldassare, A.; Fiechtner, J.; Filipowicz-Sosnowska, A. Preliminary safety and efficacy of LTâR-Ig (BG9924) in the treatment of rheumatoid arthritis (RA). Arthritis Rheum., 2007, 56(Suppl 9), S394.
123. Bingham, C.O. Emerging Therapeutics for Rheumatoid Arthritis. Bull. NYU Hosp. Jt Dis., 2008, 66(3), 210-215.
124. McInnes, I.B.; Liew, F.Y. Cytokine networks-towards new therapies for rheumatoid arthritis. Nat. Clin. Pract. Rheumatol., 2005, 1, 31-39.
125. Mackay, F.; Browning, JL. BAFF: a fundamental survival factor for B cells. Nat. Rev. Immunol., 2002, 2, 465-475.
126. Kalled, S.L. The role of BAFF in immune function and implications for autoimmunity. Immunol. Rev., 2005, 204, 43-54.
127. Ng, L.G.; Sutherland, A.P.R.; Newton, R.; Qian, F.; Cachero, TG.; Scott, ML.; Thompson, J.S.; Wheway, J.; Chtanova, T.; Groom, J.; Sutton, IJ.; Xin, C.; Tangye, S.G.; Kalled, S.L.; Mackay, F.; Mackay, C.R. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J. Immunol., 2004, 173, 807-817.
128. Dillon, S.R.; Gross, J.A.; Ansell, S.M.; Novak, A.J. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat. Rev. Drug Discov., 2006, 5, 235-246.
129. Tak, P.P.; Thurlings, R.M.; Rossier, C.; Nestorov, I.; Dimic, A.; Mircetic, V.; Rischmueller, M.; Nasonov, E.; Shmidt, E.; Emery, P.; Munafo, A. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, doubleblind, placebo-controlled, dose-escalating, single-and repeated dose study. Arthritis Rheum., 2008, 58, 61-72.
130. McClung, M.R.; Lewiecki, E.M.; Cohen, S.B.; Bolognese, M.A.; Woodson, G.C.; Moffett, A.H.; Peacock, M.; Miller, P.D.; Lederman, S.N.; Chesnut, C.H.; Lain, D.; Kivitz, A.J.; Holloway, D.L.; Zhang, C.; Peterson, M.C.; Bekker, P.J. AMG 162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med., 2006, 354, 821-831.
131. Cohen, S.B.; Valen, P.; Ritchlin, C.; Schechtman, J.; Peterfy, C.; van der Heijde, D.; Zhou, L.; Newmark, R.; Tsuji, W. RANKL inhibition with denosumab reduces progression of bone erosions in patients with rheumatoid arthritis: month 6 MRI results. Arthritis Rheum., 2006, 54, S831.
132. Redlich, K.; Hayer, S.; Maier, A. Tumor necrosis factor α-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum., 2002, 46, 785-792.
133. Jarrett, S.J.; Conaghan, P.G.; Sloan, V.S.; Papanastasiou, P.; Ortmann, CE.; O'Connor, PJ.; Grainger, AJ.; Emery, P. Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum., 2006, 54, 1410-1414.
134. Cohen, SB.; Dore, RK.; Lane, NE.; Ory, PA.; Peterfy, CG.; Sharp, JT.; van der Heijde, D.; Zhou, L.; Tsuji, W.; Newmark, R. Denosumab Rheumatoid Arthritis Study Group. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum., 2008, 58, 1299-1309.